-
- Comment on:
-
N Engl J Med. 2007 Jan 11;356(2):115-24.
-
N Engl J Med. 2007 Jan 11;356(2):125-34.
Renal-cell carcinoma--molecular pathways and therapies.
PMID: 17215538 [PubMed - indexed for MEDLINE]
-
Cited by 4 PubMed Central articles
-
Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer.
Seruga B, Gan HK, Knox JJ.
Curr Oncol. 2009 May; 16 Suppl 1:S52-9.
[Curr Oncol. 2009]
-
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, del Muro XG, et al.
Mar Drugs. 2009; 7(1):57-70. Epub 2009 Mar 5.
[Mar Drugs. 2009]
-
ReviewTissue-based research in kidney cancer: current challenges and future directions.
Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, et al.
Clin Cancer Res. 2008 Jun 15; 14(12):3699-705.
[Clin Cancer Res. 2008]
- » See all...
Patient Drug Information
-
Sorafenib (Nexavar® )
Sorafenib is used to treat advanced renal cell carcinoma (a type of cancer that begins in the kidneys). Sorafenib is in a class of medications called multikinase inhibitors. It works by slowing the spread of cancer cells...
-
Sunitinib (Sutent® )
Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in people with tumors that wer...